TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.


Options:
A: Arm Label: Fondaparinux 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Intervention Type: DRUG; Name: Fondaparinux 2.5mg or placebo; Assigned to Arm(s): Fondaparinux 2.5mg, Placebo
B: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux
C: Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: SanOrg34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: LMW heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin K antagonist (VKA); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.


Options:
A: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: SanOrg34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: LMW heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin K antagonist (VKA); Assigned to Arm(s): N/A
C: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
D: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Brief Summary: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.


Options:
A: Arm Label: Clopidogrel group; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor group; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel group | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 2
C: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel, Drug: Commercially-available Aspirin | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Commercially-available Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Commercially-available Aspirin; Assigned to Arm(s): Clopidogrel, Prasugrel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Brief Summary: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholecalciferol; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AV fistula with VasQ; Type: EXPERIMENTAL; Interventions: Device: VasQ | Arm Label: AV fistula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: VasQ; Assigned to Arm(s): AV fistula with VasQ

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Brief Summary: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.


Options:
A: Intervention Type: DEVICE; Name: Stent or stent-graft deployment; Assigned to Arm(s): N/A
B: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Conventional Balloon Angioplasty (COBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: Drug Eluting Balloon Angioplasty (DEB); Type: EXPERIMENTAL; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Drug Eluting Balloon Angioplasty (DEB) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Conventional Balloon Angioplasty (COBA)
D: Arm Label: FLAIR; Type: EXPERIMENTAL; Interventions: Device: FLAIR Endovascular Stent Graft | Arm Label: PTA Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PTA | Arm Label: FLAIR Roll-in Participants; Type: EXPERIMENTAL; Interventions: Device: FLAIR Endovascular Stent Graft | Intervention Type: DEVICE; Name: FLAIR Endovascular Stent Graft; Assigned to Arm(s): FLAIR | Intervention Type: PROCEDURE; Name: PTA; Assigned to Arm(s): PTA Only | Intervention Type: DEVICE; Name: FLAIR Endovascular Stent Graft; Assigned to Arm(s): FLAIR Roll-in Participants

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Brief Summary: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.


Options:
A: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): 2, PRT-201
C: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)
D: Arm Label: control group; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: Far infrared therapy; Type: EXPERIMENTAL; Interventions: Device: WSTM TY101 FIR emitter (Far infrared therapy) | Intervention Type: DEVICE; Name: WSTM TY101 FIR emitter (Far infrared therapy); Assigned to Arm(s): Far infrared therapy | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Many overweight patients are able to lose weight successfully, but then regain their weight. The purpose of this study is to develop and test the efficacy of 2 interventions to prevent weight regain in individuals who have recently lost weight. The two interventions being tested are a face-to-face group maintenance program and an Internet intervention. These interventions will be compared to a no-contact control group that receives quarterly newsletters. The primary outcome measure is weight regain from baseline to 18-months.


Options:
A: Intervention Type: BEHAVIORAL; Name: Behavior change on physical activity and diet; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Face-to-face maintenance program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet maintenance program; Assigned to Arm(s): N/A
C: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control
D: Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents
Brief Summary: The purpose of this study is to determine the safety and effectiveness of Depakote ER (Divalproex Sodium Extended-Release Tablets) compared to placebo in the treatment of bipolar disorder, manic or mixed type in children and adolescents ages 10-17 years.


Options:
A: Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lithium carbonate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Lithium carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 3
C: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: Divalproex sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex Sodium | Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): Divalproex sodium | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone
D: Intervention Type: DRUG; Name: Divalproex Sodium Extended-Release Tablets; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia
Brief Summary: The purpose of this study is to determine if intravenous micronutrient therapy (IVMT) is effective in the treatment of fibromyalgia, as assessed by validated functional and pain measures.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
B: Arm Label: Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saizen® | Arm Label: Placebo + Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo and Saizen® | Intervention Type: DRUG; Name: Saizen®; Assigned to Arm(s): Saizen® | Intervention Type: DRUG; Name: Placebo and Saizen®; Assigned to Arm(s): Placebo + Saizen®
C: Intervention Type: DRUG; Name: sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amitriptyline, fluoxetine and tramadol alone (control group); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Intravenous micronutrient therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples
Brief Summary: Prevention of unplanned pregnancies among HIV infected couples decreases the rate of maternal-child virus transmission and the number of children orphaned when parents die of AIDS. This study will evaluate two programs for reducing the number of unplanned pregnancies among HIV infected couples in Zambia.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: follow-up phone counseling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: follow-up phone counseling; Assigned to Arm(s): Treatment
B: Arm Label: Acyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Generic acyclovir | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Generic acyclovir; Assigned to Arm(s): Acyclovir | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)
D: Intervention Type: BEHAVIORAL; Name: User-independent contraception program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Future Planning Perspectives program; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples
Brief Summary: Prevention of unplanned pregnancies among HIV infected couples decreases the rate of maternal-child virus transmission and the number of children orphaned when parents die of AIDS. This study will evaluate two programs for reducing the number of unplanned pregnancies among HIV infected couples in Zambia.


Options:
A: Intervention Type: BEHAVIORAL; Name: User-independent contraception program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Future Planning Perspectives program; Assigned to Arm(s): N/A
B: Arm Label: Acyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Generic acyclovir | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Generic acyclovir; Assigned to Arm(s): Acyclovir | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
D: Arm Label: Integrated FP /PNC service delivery; Type: EXPERIMENTAL; Interventions: Procedure: Integrated FP/PNC service delivery | Arm Label: Non-integrated FP/PNC service delivery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Integrated FP/PNC service delivery; Assigned to Arm(s): Integrated FP /PNC service delivery

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lifestyle Changes to Increase Bone Density in Teen Girls
Brief Summary: Osteoporosis affects nearly half of all American women over age 50. During the teenage years, girls can increase bone growth to decrease their risk of osteoporosis later in life. This study will test whether girls can change their food intake and physical activity patterns in ways that will increase their bone growth during the mid-teen years.


Options:
A: Arm Label: After school sports; Type: EXPERIMENTAL; Interventions: Behavioral: After school sports program | Arm Label: After school health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: After school health education | Intervention Type: BEHAVIORAL; Name: After school sports program; Assigned to Arm(s): After school sports | Intervention Type: BEHAVIORAL; Name: After school health education; Assigned to Arm(s): After school health education
B: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Diet with increased fruits, vegetables, and calcium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased high impact activity and resistance training; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program; Assigned to Arm(s): N/A

Answer: C